Genmab A (GNMSF) Non-Current Receivables (2023 - 2025)
Historic Non-Current Receivables for Genmab A (GNMSF) over the last 3 years, with Q4 2025 value amounting to $1.1 billion.
- Genmab A's Non-Current Receivables rose 2047.67% to $1.1 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.1 billion, marking a year-over-year increase of 2047.67%. This contributed to the annual value of $1.1 billion for FY2025, which is 2047.67% up from last year.
- As of Q4 2025, Genmab A's Non-Current Receivables stood at $1.1 billion, which was up 2047.67% from $1.0 billion recorded in Q3 2025.
- In the past 5 years, Genmab A's Non-Current Receivables registered a high of $1.1 billion during Q4 2025, and its lowest value of -$193.0 million during Q3 2024.
- For the 3-year period, Genmab A's Non-Current Receivables averaged around $470.1 million, with its median value being $733.0 million (2023).
- The largest annual percentage gain for Genmab A's Non-Current Receivables in the last 5 years was 194871.79% (2025), contrasted with its biggest fall of 2047.67% (2025).
- Quarter analysis of 3 years shows Genmab A's Non-Current Receivables stood at $733.0 million in 2023, then grew by 25.92% to $923.0 million in 2024, then rose by 20.48% to $1.1 billion in 2025.
- Its last three reported values are $1.1 billion in Q4 2025, $1.0 billion for Q3 2025, and -$77.0 million during Q2 2025.